267 related articles for article (PubMed ID: 34103350)
1. Transforming the Care of Patients with Diabetic Kidney Disease.
Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade.
Shenoy SV; Nagaraju SP; Bhojaraja MV; Prabhu RA; Rangaswamy D; Rao IR
Nephrology (Carlton); 2021 Nov; 26(11):858-871. PubMed ID: 34176194
[TBL] [Abstract][Full Text] [Related]
3. Dual renin-angiotensin system blockade for nephroprotection.
Ruggenenti P
Nephrol Ther; 2017 Apr; 13 Suppl 1():S43-S45. PubMed ID: 28577742
[TBL] [Abstract][Full Text] [Related]
4. Preserving Kidney Function Instead of Replacing It.
Kliger AS; Brosius FC;
Clin J Am Soc Nephrol; 2020 Jan; 15(1):129-131. PubMed ID: 31594804
[No Abstract] [Full Text] [Related]
5. Pharmacological Management of Diabetic Nephropathy.
Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
[TBL] [Abstract][Full Text] [Related]
6. Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy.
van der Sande NG; Dorresteijn JA; Visseren FL; Dwyer JP; Blankestijn PJ; van der Graaf Y; Heerspink HL
Diabetes Obes Metab; 2016 Nov; 18(11):1120-1127. PubMed ID: 27337598
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Kidney Disease.
Tong L; Adler SG
Clin J Am Soc Nephrol; 2018 Feb; 13(2):335-338. PubMed ID: 29046291
[No Abstract] [Full Text] [Related]
8. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
St Peter WL; Odum LE; Whaley-Connell AT
Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
[TBL] [Abstract][Full Text] [Related]
9. Update concept of the dual blocking of the renin-angiotensin-aldosteron system. A new therapeutic option?
León Jiménez D; Castilla Guerra L; López Chozas JM; Miramontes González JP
Med Clin (Barc); 2018 Jan; 150(1):33-38. PubMed ID: 28668172
[No Abstract] [Full Text] [Related]
10. Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
Vart P; Vaduganathan M; Jongs N; Remuzzi G; Wheeler DC; Hou FF; McCausland F; Chertow GM; Heerspink HJL
Clin J Am Soc Nephrol; 2022 Dec; 17(12):1754-1762. PubMed ID: 36414316
[TBL] [Abstract][Full Text] [Related]
11. 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.
Fernández-Juárez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Lahera V; Casas L; Oliva J;
Clin J Am Soc Nephrol; 2013 Nov; 8(11):1870-6. PubMed ID: 24135218
[TBL] [Abstract][Full Text] [Related]
12. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.
Zanella MT; Ribeiro AB
Clin Ther; 2002 Jul; 24(7):1019-34. PubMed ID: 12182249
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for the management of special populations: renal disease in diabetes.
Raij L
Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
[TBL] [Abstract][Full Text] [Related]
14. Present and future in the treatment of diabetic kidney disease.
Quiroga B; Arroyo D; de Arriba G
J Diabetes Res; 2015; 2015():801348. PubMed ID: 25945357
[TBL] [Abstract][Full Text] [Related]
15. Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.
Soares AE; Maes M; Godeny P; Matsumoto AK; Barbosa DS; da Silva TAF; Souza FHMO; Delfino VDA
Life Sci; 2017 Dec; 191():175-179. PubMed ID: 29079468
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.
Pisoni R; Faraone R; Ruggenent P; Remuzzi G
J Nephrol; 2002; 15(4):428-30. PubMed ID: 12243375
[TBL] [Abstract][Full Text] [Related]
17. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
18. Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases.
Bramlage P; Lanzinger S; van Mark G; Hess E; Fahrner S; Heyer CHJ; Friebe M; Seufert J; Danne T; Holl RW
Cardiovasc Diabetol; 2019 Mar; 18(1):33. PubMed ID: 30878037
[TBL] [Abstract][Full Text] [Related]
19. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy.
Heerspink HJL; Andress DL; Bakris G; Brennan JJ; Correa-Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J; Perkovic V; Tobe S; Wigderson M; Parving HH; de Zeeuw D
Diabetes Obes Metab; 2018 Jun; 20(6):1369-1376. PubMed ID: 29405626
[TBL] [Abstract][Full Text] [Related]
20. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
